Compare RCMT & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | SGHT |
|---|---|---|
| Founded | 1971 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.0M | 235.0M |
| IPO Year | 1997 | 2021 |
| Metric | RCMT | SGHT |
|---|---|---|
| Price | $27.77 | $5.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $36.00 | $9.08 |
| AVG Volume (30 Days) | 74.5K | ★ 134.7K |
| Earning Date | 04-03-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.38 | ★ 28.16 |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $186,737,000.00 | $77,363,000.00 |
| Revenue This Year | $11.89 | $11.67 |
| Revenue Next Year | $12.46 | $10.39 |
| P/E Ratio | $52.83 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $17.26 | $3.11 |
| 52 Week High | $32.50 | $9.24 |
| Indicator | RCMT | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 66.52 | 65.14 |
| Support Level | $17.77 | $4.76 |
| Resistance Level | $32.39 | $5.66 |
| Average True Range (ATR) | 1.18 | 0.31 |
| MACD | 0.47 | 0.06 |
| Stochastic Oscillator | 88.80 | 76.25 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.